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Anticoagulation is highly effective in preventing stroke due to atrial fibrillation, but numerous
studies have demonstrated low utilization of anticoagulation for these patients. Assess-
ment of clinicians’ attitudes on this topic indicate that fear of intracerebral hemorrhage
(ICH), rather than appreciation of anticoagulation benefits, largely drives clinical decision-
making for treatment with anticoagulation in atrial fibrillation. Risk stratification strategies
have been used for anticoagulation benefits and hemorrhage risk, but ICH is not specif-
ically addressed in the commonly used hemorrhage risk stratification systems. Cerebral
microbleeds are cerebral microscopic hemorrhages demonstrable by brain MRI, indica-
tive of prior microhemorrhages, and predictive of future risk of ICH. Prevalence of cerebral
microbleeds increases with age; and cross-sectional and limited prospective studies gener-
ally indicate that microbleeds confer substantial risk of ICH in patients treated with chronic
anticoagulation. MRI thus is a readily available and appealing modality that can directly
assess risk of future ICH in patients receiving anticoagulants for atrial fibrillation. Incor-
poration of MRI into routine practice is, however, fraught with difficulties, including the
uncertain relationship between number and location of microbleeds and ICH risk, as well
as cost-effectiveness of MRI. A proposed algorithm is provided, and relevant advantages
and disadvantages are discussed. At present, MRI screening appears most appropriate for
a subset of atrial fibrillation patients, such as those with intermediate stroke risk, and may
provide reassurance for clinicians whose concerns for ICH tend to outweigh benefits of
anticoagulation.
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INTRODUCTION
Stroke prevention relies on chronic anticoagulation in an increas-
ingly selective fashion. Well-constructed clinical trials have led to
a nearly exclusive focus on chronic anticoagulation for prevention
of cardiogenic stroke, specifically stroke prevention in patients
with atrial fibrillation. Given the well-known high morbidity and
mortality of cardiogenic stroke and the high degree of preventabil-
ity of these events, one might assume that clinicians are highly
motivated to aggressively initiate anticoagulation for patients with
atrial fibrillation in an attempt to eliminate this most devastating
consequence of that arrhythmia. But this assumption may not be
correct; anticoagulation is underutilized in this population.
This article will review issues underlying this underutilization
of anticoagulation, the reasons for avoidance of highly effective
treatment for a devastating disorder, and offer a possible way out
of this predicament with better targeting of patients likely to bene-
fit from this treatment. An important issue implicit in this clinical
problem is the coexistence of ischemic and hemorrhagic cere-
brovascular disease, necessitating new diagnostic terminologies.
This paper will explore the potential benefits of using high quality
brain imaging for risk stratification for anticoagulant-associated
intracerebral hemorrhage (ICH), and discuss how this may be
incorporated into clinical practice in a manner that will lead to
substantial improvements in stroke prevention.
UNDERUTILIZATION OF ANTICOAGULATION FOR ATRIAL
FIBRILLATION
Precise numbers regarding anticoagulation utilization can be dif-
ficult to obtain from the literature, due to the necessity for distin-
guishing patients receiving anticoagulants and then discontinuing
usage, vs. those patients who continued to take anticoagulants for
a prolonged period of time. One careful study showed increas-
ing warfarin utilization through the survey period of 1992–2002,
peaking at 56.3% in 2002, with 59.9% usage in patients lack-
ing risk factors for falls and bleeding (1). A follow-up study
reported continued rise in warfarin utilization, peaking at 63.1%
in 2007 (2).
Other studies have been less encouraging. For example, a survey
of anticoagulant use world-wide reported that half of the analyzed
studies (15/29) described treatment with anticoagulation in less
than half of high risk atrial fibrillation patients (3), while more
than half of the studies (21/29) reported anticoagulation usage in
<60% of patients with prior stroke or transient ischemic attack
(3). A recent Canadian study reported usage of anticoagulation
in 49% of older patients (aged 65 and older) with atrial fibrilla-
tion, with no relationship between anticoagulation use and stroke
risk (4). Among more than 1,100 patients in an American primary
care population (mean age 70 years), 67% were treated with anti-
coagulants, but treatment was discontinued in 25.4% within 1 year
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and at end of follow-up period (mean 3.4 years) 45.7% remained
on warfarin (5). Inappropriate discontinuation of anticoagulation
appears to be a significant problem, and is associated with excessive
thrombotic risk (6). A survey of more than 13,000 American nurs-
ing home residents revealed warfarin usage in 30% of patients with
atrial fibrillation (7). Another recent analysis,of more than 170,000
patients, reported that warfarin was prescribed for a similar pro-
portion of patients regardless of whether their stroke risk was low
(40.1%), medium (43.5%), or high (42.1%); moreover, only 32.8%
of patients received 6 months of uninterrupted warfarin therapy
for stroke prevention (8).
This rather robust literature on use of anticoagulation for atrial
fibrillation patients thus shows substantial variation. Utilization of
anticoagulation varies from a high end just over 60%, to a low end
of 30% in nursing homes. At the very least, there is considerable
room for improvement.
EFFECTIVENESS OF ANTICOAGULATION FOR PREVENTION
OF CARDIOGENIC STROKE
The low utilization of anticoagulation for atrial fibrillation patients
could perhaps be understood in the context of therapeutic inef-
fectiveness. But this is hardly the case. Individual trials as well
as pooled analyses have demonstrated an estimated 65–68%
stroke reduction by warfarin (9, 10). Moreover, atrial fibrillation-
associated strokes are among the most devastating: compared to
non-atrial fibrillation-associated strokes, there is greater severity,
more disability, nearly twice likelihood to have in-hospital medical
complications (43.3 vs. 24.4%), longer hospital stay (15 vs. 9 days),
and more than double both short-term (30 days) mortality (14.7
vs. 5.8%) and long-term (1 year) mortality (31.7 vs. 13.7%) (11).
Stroke due to atrial fibrillation is therefore among the most severe
while simultaneously being among the most preventable cerebral
ischemic events.
REASONS FOR UNDERUTILIZATION: IGNORANCE OR FEAR?
Rather than bemoan the underutilization of anticoagulants for
atrial fibrillation-associated stroke, a more useful approach is
to attempt to understand the underlying causes of this unusual
behavior among clinicians. It is typically assumed that low uti-
lization of effective therapy reflects lack of knowledge or frank
ignorance of the benefits provided by anticoagulation in this set-
ting. However, a critical assessment of physician’s attitudes shed
some light on this topic. A survey of 30 studies indicated that
physicians are reluctant to prescribe anticoagulation for older
patients with atrial fibrillation because of excessive concern for
prior hemorrhage and fall risk (12). In a particularly well-detailed
and systematic survey of clinicians’ attitudes toward anticoagula-
tion for atrial fibrillation, there was no relationship between use of
warfarin and its perceived benefits (13). On the contrary, decision-
making was largely driven by fear, with an overarching concern
regarding ICH as a consequence of warfarin use (13). Physicians
anticipating regret over ICH from warfarin were approximately
80% less likely to recommend warfarin in case vignettes. Moreover,
risks of ICH were consistently overestimated, at a rate far higher
than reported in the literature (13). Thus, a principal driving force
for underutilization of anticoagulation relates to concern for hem-
orrhage, specifically ICH, as an adverse effect. The actual risk of
ICH with warfarin use in this population is typically viewed as
ranging from 0.3 to 1% annual risk (14), although first year risks
as high as 2.5% have been reported (15). Newer anticoagulants
include dabigatran (direct thrombin inhibitor) and rivaroxaban
(factor Xa inhibitor), which reportedly reduce risk of intracere-
bral hemorrhage by as much as one-third (rivaroxaban vs. war-
farin) and 60% (dabigatran vs. warfarin) (16, 17). While it is not
known how use of these newer agents impacts decision-making
for anticoagulation in atrial fibrillation, it has been estimated that
threshold stroke risk for triggering anticoagulation may be low-
ered (18). Nevertheless, reversibility of these agents has remained
a concern (19).
RISK STRATIFICATION STRATEGIES: SUCCESS AND FAILURE
Risk stratification paradigms are an attractive option for address-
ing and potentially correcting the underutilization of anticoagu-
lation for stroke prevention in atrial fibrillation. In fact, there are
now a number of these point systems available. These strategies all
have their acronyms, and represent a serious attempt to provide a
quick assessment of risks.
Stroke risk with atrial fibrillation has been most frequently
addressed with the CHADS2 system. The simplicity of CHADS2
is appealing, with one point given for congestive heart failure,
hypertension, age>75 years, diabetes, and two points for stroke or
TIA. A modification of CHADS2 is the CHA2DS2-VASc system,
in which stroke risk is stratified by giving points for congestive
heart failure or left ventricular dysfunction, hypertension, age
75 or older (two points), diabetes, stroke (two points), vascu-
lar disease, age 65–74, and sex category (one point for females)
(20). The initial CHADS2 system has the advantage of the two
by virtue of its simplicity, but neither address hemorrhage risk.
And as described above, decision-making for anticoagulation is
substantially impacted by fear of ICH.
As an alternate or supplement to stroke risk-driven strati-
fication systems, at least three major classifications have been
used to address hemorrhage risk. The HEMORR2HAGES sys-
tem gives two points for a prior hemorrhage, with one point
for risk factors hepatic or renal disease, ethanol abuse, malig-
nancy, age >75 years, reduced platelet count or function, hyper-
tension (uncontrolled), anemia, genetic factors, excessive fall risk,
and stroke (21). Aside from the relative complexity of this sys-
tem, hemorrhage prediction with this system focuses largely on
gastrointestinal hemorrhages (21).
A later system developed for assessing hemorrhage risk is the
ATRIA paradigm, in which variable number of points are given
for anemia (three points), severe renal disease (three points), age
75 or older (two points), prior bleeding (one point), and hyper-
tension (one point) (22). This system appears to be effective for
predicting overall hemorrhage risk, with rates of 0.4% for 0 points
and 17.3% annual hemorrhage risk for 10 points (22). However,
this system makes no attempt to differentiate ICH risk from risks
of other forms of hemorrhage.
A third system, HAS-BLED has been shown to be more effica-
cious in hemorrhage prediction, compared to HEMORR2HAGES
and ATRIA (23). HAS-BLED allocates one point each for hyper-
tension, abnormal renal or liver function, stroke, bleeding, labile
INR, elderly (>65 years), and drugs or alcohol. HAS-BLED was
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significantly better for hemorrhage prediction than the other two
systems, but overall predictive performance for both major bleed-
ing and clinically relevant bleeding was considered modest (23).
On the other hand, HAS-BLED was the only one of the three
systems that had predictive value for ICH. This latter predictive
performance was considered “good,” although predictive power
was only mid-way between chance and perfect discrimination for
future ICH, and overall effectiveness of HAS-BLED was largely
focused on bleeding events that were not considered “major” (i.e.,
non-ICH) (23).
In summary, these risk stratification systems have some effec-
tiveness in both predicting atrial fibrillation-related stroke and
warfarin-related hemorrhage. However, underutilization of anti-
coagulation appears to be less related to extent of appreciation of
its stroke-preventing benefits and more driven by decision-making
that has become distorted by over-emphasis on hemorrhagic risks.
Moreover, the risk of the adverse event of greatest concern (ICH)
is not directly addressed by the standard hemorrhage stratification
systems, which primarily predict gastrointestinal hemorrhage. It
would appear that a rather different approach is indicated.
CEREBRAL MICROBLEEDS AS RISK-INDICATORS FOR
INTRACEREBRAL HEMORRHAGE
Cerebral microbleeds are MRI-demonstrable signatures of small
areas of brain hemorrhage. These hemorrhagic areas are seen on
gradient echo and susceptibility-weighted imaging, and show a
striking age-dependent increasing prevalence varying from 6.5%
in individuals aged 45–50, 11.5% for ages 50–59 years, 16.8%
for ages 60–69 years, and 35.7% for persons age 80 and older
(24). The consensus view is that cortical microbleeds tend to be
manifestations of cerebral amyloid angiopathy, while deep hemi-
sphere lesions are indicative of hypertensive arteriopathy (24). The
underlying pathological substrate has been thought to depend on
small arterial tears (25), although capillary-derived hemorrhage
has been suggested as an alternate source (26).
There is a powerful relationship between cerebral microbleeds
and ICH. Prevalence of microbleeds in subjects with spontaneous
ICH is 68% (27), and up to 64% among ICH subjects and coex-
isting TIA/ischemic stroke (28). It is unclear whether microbleeds
are the source of these hemorrhages or simply reflect another form
of vascular injury predisposing to clinical hemorrhage.
Given these high prevalence rates, the relationship between
microbleeds and ICH among patients using anticoagulants
becomes of great interest. The importance of this issue was
emphasized by the report of Lee et al (29), in which presence
of microbleeds appeared to confer a more than 83-fold increased
risk of warfarin-associated ICH; number of microbleeds was also
associated with hemorrhage risk, as was location (lobar, basal gan-
glia, and cerebellum). This study was based on a cross-sectional
case-control investigation, in which microbleeds associated with
intracerebral hemorrhage were excluded. This report was notable
as a stunningly high risk assessment for microbleeds in this popu-
lation, raising the possibility that presence of microbleeds could be
an important marker for warfarin-associated ICH. Note, however,
the large confidence intervals (5.96–1,159.10) for the findings of
the yet-to-be reproduced 83-fold increased risk. Another report,
by Soo et al. (30), explored the relationship between numbers of
microbleeds and ICH risk, and found that those patients with five
or more microbleeds were at highest risk for ICH (7.6%), com-
pared to those with zero, one, and two to four microbleeds (0.6,
1.9, and 4.6%, respectively); however, the overwhelming major-
ity of these patients were using platelet medications rather than
anticoagulants.
The microbleeds-ICH risk has been studied in a series of sys-
tematic reviews. Presence of microbleeds in warfarin-associated
ICH was significantly increased (odds ratio 2.7), compared to
ICH without antithrombotic usage (platelet agents or anticoagu-
lants) (28). Initial pooled prospective studies reported microbleeds
conferring more than 12-fold increased risk of ICH with use of
antithrombotics (28).
More recent estimates of microbleed risk, based on pooled
prospective studies, report enhanced risk for ICH (odds ratio 8.5)
in TIA-ischemic stroke patients with microbleeds (compared to
those without microbleeds) (31). The risk for ICH (enhanced
more than 10-fold) was concentrated among Asian patients (31).
Prospective risk of ICH specifically among warfarin users with
microbleeds was based on pooled data including only five subjects
with ICH (odds ratio 3.0, p= 0.23) (27).
In summary, microbleeds often coexist with ICH and clearly
have predictive value for future ICH. Use of antithrombotic ther-
apies confers additional risk of subsequent ICH on patients with
microbleeds. Race appears to have a substantial impact on this risk,
and the relative impact of anticoagulants vs. platelet agents on this
hemorrhage risk is unclear, as is the role of newer anticoagulants.
WHITE MATTER DISEASE OF AGING AND RISK OF
INTRACEREBRAL HEMORRHAGE
Age-related white matter changes are demonstrable by MRI in
more than 95% of the population age 65 or older (32). The more
severe form of these changes, sometimes termed leukoaraiosis, are
strongly related to presence of cerebral microbleeds (33–37), sug-
gesting a common microvascular etiology for both (38). Presence
of leukoaraiosis, as demonstrated by CT, has been shown to sub-
stantially predict warfarin-related ICH with odds ratios ranging
from 2.7 to 12.9 (39, 40). Predictive value of white matter disease
shown by MRI, for anticoagulant-related ICH, is not known.
MRI SCREENING FOR MICROBLEEDS IN ANTICOAGULATION
PATIENTS
Coexistence of ischemic and hemorrhagic cerebrovascular disor-
ders creates new challenges in clinical neurology, creating the need
for a diagnostic paradigm such as “mixed cerebrovascular disease”
(41) and requiring novel strategies. The clinical problems inher-
ent in anticoagulation for atrial fibrillation substantially reflect the
difficulties raised by mixed cerebrovascular disease. Presence of
cerebral microbleeds in this population, combined with the need
for anticoagulation to prevent ischemic stroke, creates a combina-
tion of ischemic and hemorrhagic cerebrovascular processes that
can be unsettling for the clinician.
As noted previously, fear of ICH is a principal driving force in
anticoagulation decision-making. MRI screening of these patients
therefore may have some appeal as a means for addressing concerns
of clinicians faced with the risk of cardioembolic stroke and con-
current risk of brain hemorrhage. If MRI were to be used for these
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patients, how would the information so obtained be incorporated
into clinical practice?
A clinical algorithm that incorporates MRI screening into
anticoagulation decision-making for atrial fibrillation patients is
proposed (Figure 1). In this pathway, MRI screening is reserved
for patients 60 years and older, an age range in which microb-
leeds prevalence overall is expected to be approximately 20%
or more (24). Among those patients who have microbleeds
demonstrable on MRI, a distinction is made between corti-
cal microbleeds vs. subcortical microbleeds, and between find-
ings of five or more subcortical microbleeds vs. less than
five subcortical microbleeds. The rationale for these distinc-
tions is based on the likelihood of cerebral amyloid angiopa-
thy with presence of cortical microbleeds (24), and the findings
of increasing risk of intracerebral hemorrhage with increased
numbers of microbleeds (29, 30). Nevertheless, the data on which
FIGURE 1 | Proposed algorithm for incorporation of MRI screening into decision-making for anticoagulation for atrial fibrillation patients. “Newer
anticoagulants” refers to agents such as dabigatran and rivaroxaban.
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this algorithm is based are fragmentary, necessitating a con-
siderable amount of speculative extrapolation for constructing
the algorithm.
From the perspective of this algorithm, presence of cortical
microbleed(s) or at least five subcortical microbleeds would trig-
ger formal neurological consultation, to carefully focus on mental
status, gait status, assessment of what kind of supervision may
be necessary if the patient began anticoagulants, and to establish
a neurological baseline for future comparisons. Anticoagulation
with warfarin would be avoided, but new anticoagulants would be
acceptable. Any neurological changes while anticoagulated would
trigger follow-up MRI to help determine cause of progression and
address potential microbleed changes, including size and number
of microbleeds (42).
Nevertheless, such an algorithm is likely to be criticized as
lacking a substantial foundation of compelling data. Specifically,
the relationships between site and numbers of microbleeds (on
the one hand) and future bleeding risk (on the other hand)
are not that well worked out, and it has not yet been demon-
strated that the newer anticoagulants specifically have reduced
risk of ICH in patients with cerebral amyloid angiopathy. Indeed,
one might simply argue that given the overwhelming benefit
of anticoagulation in atrial fibrillation that has already been
demonstrated even in an elderly population (43), why is such
an algorithm needed? Why not simply move away from war-
farin to newer anticoagulants and initiate anticoagulation based
on ischemic stroke risk (44)? While there is a compelling logic
to these questions, they do not address the fundamental prob-
lem described earlier, i.e., the problem of substantial numbers
of clinicians avoiding anticoagulation due to excessive fear of
ICH. Risk in individual patients is not directly addressed by
the reported overall reduced risk of ICH with newer anticoag-
ulants (16, 17). In this context, MRI becomes perhaps the only
means by which those concerns may be directly addressed in a
systematic manner.
MRI SCREENING: COSTS AND BENEFITS
Any incorporation of MRI into routine clinical evaluation of atrial
fibrillation patients will raise issues of the economics involved.
A formal cost-benefit analysis for MRI screening is beyond the
scope of this paper. However, some initial observations can be
provided. Average cost of brain MRI has been reported as $2700
(45), but actual reimbursement by Medicare or other third par-
ties is considerably lower; for example, Medicare reimbursement
for a non-contrast MRI is estimated at just under $500 per scan
(www.palmettogba.com).
The population of atrial fibrillation patients in the US has
been estimated at 2.3 million (46). It is has been calculated that
expanding anticoagulation usage, to one-half of currently non-
anticoagulated patients, would result in annual savings of $1.3
billion (46). Given an at-risk population of atrial fibrillation
patients aged 60 or older conservatively estimated at two million,
justification for MRI screening of this population might require
an unrealistic expansion of anticoagulation usage.
However, Mercaldi et al. report estimated savings associated
with use of warfarin in patients with atrial fibrillation at more
than $9800 per patient per year (47). With costs of MRI scans at
Medicare rates, the analysis becomes more favorable. For example,
the cost of the scanning program may be covered if anticoagu-
lant usage was incrementally increased by approximately 5% of
patients scanned. Costs of additional neurology consults will also
impact this analysis.
The logistical exercise of performing the scans would not be
inconsequential, with a conservatively estimated 6,000 MRI scan-
ners in the US (48) needing to study two million patients; this
patient population could perhaps be covered with an additional
patient studied daily for 1 year. If a substantial proportion of MRI
scanners were incapable of performing the appropriate sequences,
i.e., gradient echo and/or susceptibility-weighted imaging (49),
there would be a commensurate enhancement of this increased
workload for those scanners that did have this capability.
This analysis is not intended to be definitive. However, it does
suggest that large-scale MRI scanning is not entirely unrealistic
from an economic perspective. The logistical issues are substantial,
but not necessarily unachievable.
CONCLUSION
MRI screening for atrial fibrillation patients, to address prospective
risk of ICH, has significant appeal. In the minds of many clinicians,
concern for hemorrhagic risk with anticoagulants outweighs bene-
fits of stroke prevention. Systemic bleeding is addressed in current
hemorrhage risk stratification systems, and incorporation of MRI
findings into formal risk stratification efforts would be welcome.
However, there are a number of factors that suggest a cautious
approach to this issue. Potential problems, while not necessarily
insurmountable, are also not insignificant. These issues include
the logistical demands of large-scale MRI screening of atrial fibril-
lation patients, the uncertain extent of enhanced usage of antico-
agulation resulting from MRI screening, the limited data on risk
impact of number and sites of cerebral microbleeds, and the pro-
found costs involved. Ongoing prospective trials are expected to
provide definitive guidance (50).
Perhaps the most attractive strategy is a limited incorpora-
tion of MRI screening in order to optimize patient selection for
chronic anticoagulation. Such an intermediate path would incor-
porate MRI screening not routinely, but in the settings of patients
with intermediate CHADS2 scores (e.g., scores of 1–2), for patients
whose fall risks and/or mental status changes creates heightened
concerns regarding risk for ICH, and for those clinicians whose
concerns for ICH risk typically predominate in their decision-
making for anticoagulation recommendations in patients with
atrial fibrillation. For these subsets, an algorithm as described
herein may be useful for providing a means for systematic eval-
uation of microbleeds and ICH risk in a patient population that
remains undertreated. With this approach, increased utilization of
anticoagulation is likely to be incremental but nevertheless ben-
eficial given the devastating consequences of stroke due to atrial
fibrillation.
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